Dr.Ju-YingJiang Taiwan

Dr.Ju-YingJiang
Dr. Jiang is currently the Head of the Department of Endocrinology and Metabolism at Far Eastern Memorial Hospital, New Taipei City, Taiwan. She also serves as a lecturer in the Department of Medical Information and Management at Ming Chuan University. She earned her medical degree from National Taiwan University and completed her professional training in Internal Medicine as well as Endocrinology and Metabolism at National Taiwan University Hospital. She later obtained a Master of Science degree from the Graduate Institute of Health Policy and Management, College of Public Health, National Taiwan University. Dr. Jiang is board-certified in Internal Medicine and in Endocrinology and Metabolism in Taiwan. She is a member of the Taiwan Society of Internal Medicine, the Endocrine Society of the Republic of China (Taiwan ), the Diabetes Association of the Republic of China (Taiwan), Taiwanese Association of Diabetes Educators (TADE), and the Asian Association for the Study of Diabetes (AASD). As an attending physician, Dr. Jiang provides both outpatient and inpatient care for patients with diabetes. She also serves as the principal investigator in multiple international, multicenter Phase II, III and IV clinical trials related to diabetes. In addition, Dr. Jiang is actively involved in public health education programs and professional training, frequently delivering continuing education lectures and organizing local seminars for healthcare professionals.

22 MARCH

Time Session
14:00
15:30
[DAROC Symposium 5] Medication
Insulin Therapy Across the Spectrum of Diabetes
  • Insulin as Lifeline: Optimizing Regimens in Type 1 Diabetes
    Yi-Ching TungTaiwan Speaker Insulin as Lifeline: Optimizing Regimens in Type 1 Diabetes
  • When, What, and How: Practical Approaches to Insulin Use in Type 2 Diabetes
    Ju-Ying JiangTaiwan Speaker When, What, and How: Practical Approaches to Insulin Use in Type 2 DiabetesPractical insulin use in type 2 diabetes (T2D) requires clear decisions on when to start therapy, what regimen to choose, and how to titrate effectively. Insulin is indicated when lifestyle measures and non-insulin medications fail to achieve glycemic goals, especially when Hba1c is ≥10%, fasting glucose is >250–300 mg/dL, or when patients show symptomatic hyperglycemia or catabolic features. Insulin is also required during acute illness, surgery, pregnancy, or corticosteroid use. Basal insulin remains the preferred first step due to its simplicity and lower hypoglycemia risk. Long-acting insulin analogues such as Glargine or Degludec are commonly initiated at 10 units or 0.1–0.2 U/kg/day with stepwise titration. When additional blood sugar control is needed, options include adding a GLP-1 receptor agonist, moving to basal-plus or basal-bolus regimens, or using premixed insulin for patients with fixed routines. Importantly, once-weekly basal insulin formulations—such as insulin icodec—are emerging as a future option, offering flatter pharmacokinetics and the potential to improve adherence by reducing injection frequency. These agents may simplify initiation and long-term management for patients hesitant about daily injections. Overall, individualized regimen selection, structured titration, and patient-centered education remain essential for safe and effective insulin therapy.
  • The New Era of Insulin Therapy: Ultra-Long Acting, Smart Delivery, and Beyond
    Jia-Hong Lin Speaker The New Era of Insulin Therapy: Ultra-Long Acting, Smart Delivery, and Beyond
102